LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
As fresh data confirm the promise of RNAi technology in hepatitis B, Assembly brings on Arbutus for its combo strategy.
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
The first data with the RNAi project VIR-2218 mark Vir’s attempt to join a race that Arbutus appeared to crash out of last month.
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.